Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 463,600 shares, a growth of 15.4% from the January 15th total of 401,900 shares. Based on an average trading volume of 58,300 shares, the days-to-cover ratio is presently 8.0 days. Currently, 3.0% of the shares of the company are sold short.

Accelerate Diagnostics Stock Performance

AXDX stock traded down $0.01 during trading hours on Friday, reaching $1.18. The stock had a trading volume of 26,100 shares, compared to its average volume of 38,417. The stock has a 50-day simple moving average of $1.21 and a 200 day simple moving average of $1.54. Accelerate Diagnostics has a fifty-two week low of $0.73 and a fifty-two week high of $2.09.

Wall Street Analyst Weigh In

Several analysts have recently commented on AXDX shares. BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com began coverage on shares of Accelerate Diagnostics in a research report on Thursday. They set a “hold” rating on the stock.

Insider Activity

In other Accelerate Diagnostics news, Director John Patience acquired 200,000 shares of Accelerate Diagnostics stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average cost of $1.57 per share, with a total value of $314,000.00. Following the acquisition, the director now owns 653,224 shares of the company’s stock, valued at approximately $1,025,561.68. The trade was a 44.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 43.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Accelerate Diagnostics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in Accelerate Diagnostics during the 4th quarter worth approximately $27,000. Y Intercept Hong Kong Ltd acquired a new stake in Accelerate Diagnostics during the 3rd quarter worth approximately $34,000. Renaissance Technologies LLC boosted its position in Accelerate Diagnostics by 160.6% during the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after buying an additional 65,984 shares during the period. Finally, Geode Capital Management LLC boosted its position in Accelerate Diagnostics by 6.9% during the 4th quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock worth $163,000 after buying an additional 8,777 shares during the period. Institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.